Virgo Health nets UK account for Bonviva

Virgo Health PR has scooped a UK contract to promote Bonviva, an osteoporosis treatment being co-developed by Roche and GlaxoSmithKline.

Bonviva, a bisphosphonate-classed drug, will help prevent and treat post-menopausal osteoporosis. Roche and GSK hope to launch the product in the UK next year.

Virgo is understood to have beaten Chandler Chicco Agency, Ketchum and Galliard to the account, which includes media and professional relations, plus liaison with patient groups.

Virgo, for whom agency co-founder Sarah Matthew leads the account team, reports to Roche Products pharma PR manager Susie Hackett.

European approval for Bonviva was received in February, while the US Food and Drug Administration approved a once-daily formulation of Boniva (the brand’s US name) 14 months ago. But Roche/GSK do not plan to launch the product until less frequent dosing regimens are approved.

The benefit of Bonviva by injection once every two or three months is equivalent to daily oral administration, according to a recent study.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in